Still proliferating CD44+/Ki67+ tumor cells after neoadjuvant radiochemotherapy identify rectal cancer patients with poor survival

Klose, Johannes; Schmitt, Annelene; Pernthaler, Julia; Warschkow, René; Büchler, Markus W.; Schneider, Martin; Lasitschka, Felix; Tarantino, Ignazio

doi:10.1016/j.ejso.2021.03.250

Cited by 2 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of tumor tissue mismatch repair proteins, MLH1, MSH2, MSH6, and PMS2, could reflect microsatellite instability status. The Ki67 protein is a nuclear antigen, which can objectively reflect the state of tumor cell proliferation and indicate prognosis ( 33 ); EGFR is a transmembrane glycoprotein receptor which plays an important role in tumor occurrence and progression; moreover, anti-EGFR monoclonal antibody has been approved for a good response rate and possible secondary resection of advanced CRC ( 34 ). A previous study found that HER2 overexpression correlated with more aggressive CRC in a North African population ( 35 ).…”

Section: Discussionmentioning

confidence: 99%

Correlation between apparent diffusion coefficient and tumor-stroma ratio in hybrid 18F-FDG PET/MRI: preliminary results of a rectal cancer cohort study

Xing

Liu

et al. 2022

Quant Imaging Med Surg

View full text Add to dashboard Cite

Background: To explore possible correlations between the tumor-stroma ratio (TSR) and different imaging features of fluorine-18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging ( 18 F-FDG PET/MRI) in untreated rectal cancer patients.Methods: A patients with rectal cancer were included in this study. All participants were examined preoperatively with whole-body 18 F-FDG PET/MRI. Two pathologists evaluated the TSR of tumors together. Apparent diffusion coefficient (ADC) values and PET-related parameters of the primary lesions were measured and compared between the stroma-high and stroma-low groups. Pearson's correlation or Spearman's rank correlation were used to evaluate the correlation between the ADC values, PET-related parameters, and pathological indices.Results: Our results showed that in the untreated rectal cancer patients, the ADC mean values correlated with the TSR (r=0.327; P=0.007), and stroma-high (low TSR) rectal cancer corresponded to relatively lower ADC mean values (813.54±88.68 vs. 879.92±133.18; P=0.018). The ADC mean and ADC minimum (ADCmin) values were found to be negatively correlated with the pathological T stages (r=−0.384, P=0.001; r=−0.416, P=0.001, respectively) as well as the largest tumor diameters (r=−0.340, P=0.005; r=−0.314, P=0.010, respectively) of rectal cancer. In addition, the pathological T stages correlated with all PET-related metabolic parameters, including mean standard uptake value (SUV), maximum SUV (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) (r=0.338, P=0.006; r=0.350, P=0.004; r=0.326, P=0.007; and r=0.472, P<0.001, respectively). Our results also identified associations between the ADCmin values and SUVmean, SUVmax, P=0.006; P=0.005; P=0.005, respectively). However, there were no statistical correlations between the PET/MRI parameters and the immunohistochemical (IHC) results.Conclusions: This study indicated that the intratumoral heterogeneity measured by PET/MRI may reflect characteristics of the tumor microenvironment. Hence, PET/MRI parameters might be helpful in predicting tumor aggressiveness and prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Correlation between apparent diffusion coefficient and tumor-stroma ratio in hybrid 18F-FDG PET/MRI: preliminary results of a rectal cancer cohort study

Xing

Liu

et al. 2022

Quant Imaging Med Surg

View full text Add to dashboard Cite

show abstract

“…The results were categorized according to the effect of CD44 expression on chemotherapy treatment outcome. In summary, three studies reported a positive effect of increased CD44 expression on chemotherapy treatment outcome [ 22 , 23 , 24 ], thirteen studies reported no significant effect between CD44 expression and chemotherapy treatment outcome [ 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 ], and twenty-four studies reported a significant negative effect of increased CD44 expression on chemotherapy treatment outcome [ 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 ]. These studies are summarized in Table 1 , Table 2 and Table 3 , respectively.…”

Section: Resultsmentioning

confidence: 99%

“…Studies were further stratified based on the types of interventions. Nine studies involved chemotherapy as the only treatment [ 35 , 36 , 45 , 50 , 51 , 54 , 55 , 59 , 61 ], eight studies only involved radiochemotherapy [ 23 , 24 , 29 , 31 , 34 , 38 , 49 , 56 ], fifteen studies involved chemotherapy and surgery [ 25 , 26 , 27 , 30 , 33 , 39 , 41 , 42 , 44 , 46 , 47 , 52 , 53 , 57 , 58 ], and seven studies involved chemotherapy, radiotherapy, and surgery [ 22 , 28 , 37 , 39 , 43 , 48 , 60 ]. One study involved chemotherapy and hormonal therapy [ 40 ].…”

Section: Resultsmentioning

confidence: 99%

“…The effect of CD44 expression on chemotherapy treatment outcome categorized by the most common chemotherapy drugs used in studies included in this review is reported in Table 5 (5-fluorouracil [ 28 , 31 , 32 , 33 , 35 , 37 , 38 , 41 , 43 , 46 , 47 , 48 , 60 ], cisplatin [ 23 , 29 , 30 , 33 , 34 , 38 , 39 , 46 , 49 , 58 , 61 ] and docetaxel [ 34 , 38 , 46 , 50 , 58 , 61 ]). Other drugs used include adriamycin/doxorubicin [ 30 , 46 , 50 , 56 ], cyclophosphamide [ 35 , 43 , 46 , 50 , 56 ], cetuximab [ 29 , 38 , 49 ], paclitaxel [ 22 , 35 , 59 ], epirubicin [ 39 , 43 ], carboplatin [ 22 , 38 ], and etoposide [ 39 , 45 ].…”

Section: Resultsmentioning

confidence: 99%

“…The types of cancer in the studies included in this review are breast cancer [ 25 , 26 , 35 , 40 , 43 , 50 , 51 , 52 , 53 , 57 , 59 ], rectal cancer [ 28 , 31 , 32 , 37 , 47 , 48 , 60 ], head and neck cancer [ 29 , 38 , 49 , 51 ], cervical cancer [ 23 , 34 , 39 ], esophageal cancer [ 22 , 33 , 46 ], leukemia [ 36 , 45 ], osteosarcoma [ 27 , 30 , 44 ], colon cancer [ 41 , 55 ], kidney cancer [ 42 , 54 ], gastric cancer [ 58 ], glioblastoma [ 24 ], lung cancer [ 61 ], and lymphoma [ 56 ], as summarized in Table 6 . Taken together, the results show that CD44 overexpression tends to have a predominantly negative impact on chemotherapy outcomes across various cancers, with a limited number of instances showing no effect or a potential positive effect, highlighting the complex and varied relationship between CD44 expression and treatment response in different cancer types.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Role of CD44 in Chemotherapy Treatment Outcome: A Scoping Review of Clinical Studies

Wu,

Lu,

Loo

et al. 2024

IJMS

View full text Add to dashboard Cite

Cluster of differentiation 44 (CD44), a cell surface adhesion molecule overexpressed in cancer stem cells, has been implicated in chemoresistance. This scoping review, following PRISMA-ScR guidelines, systematically identified and evaluated clinical studies on the impact of CD44 expression on chemotherapy treatment outcomes across various cancer types. The search encompassed PubMed (1985–2023) and SCOPUS (1936–2023) databases, yielding a total of 12,659 articles, of which 40 met the inclusion criteria and were included in the qualitative synthesis using a predefined data extraction table. Data collected included the cancer type, sample size, interventions, control, treatment outcome, study type, expression of CD44 variants and isoforms, and effect of CD44 on chemotherapy outcome. Most of the studies demonstrated an association between increased CD44 expression and negative chemotherapeutic outcomes such as shorter overall survival, increased tumor recurrence, and resistance to chemotherapy, indicating a potential role of CD44 upregulation in chemoresistance in cancer patients. However, a subset of studies also reported non-significant relationships or conflicting results. In summary, this scoping review highlighted the breadth of the available literature investigating the clinical association between CD44 and chemotherapeutic outcomes. Further research is required to elucidate this relationship to aid clinicians in managing CD44-positive cancer patients.

show abstract

Still proliferating CD44+/Ki67+ tumor cells after neoadjuvant radiochemotherapy identify rectal cancer patients with poor survival

Cited by 2 publications

References 33 publications

Correlation between apparent diffusion coefficient and tumor-stroma ratio in hybrid 18F-FDG PET/MRI: preliminary results of a rectal cancer cohort study

Correlation between apparent diffusion coefficient and tumor-stroma ratio in hybrid 18F-FDG PET/MRI: preliminary results of a rectal cancer cohort study

Role of CD44 in Chemotherapy Treatment Outcome: A Scoping Review of Clinical Studies

Contact Info

Product

Resources

About